Cardiovascular risk in patients with rheumatoid arthritis

Area of Science:

• Rheumatology
• Cardiovascular Medicine
• Immunology

Background:

• Rheumatoid arthritis (RA) is associated with a significantly increased risk of cardiovascular (CV) disease.
• While traditional CV risk factors play a role, inflammation is increasingly recognized as a key driver of atherosclerosis in RA patients.
• Recent research highlights the intricate relationship between inflammation and lipid metabolism in accelerating atherogenesis.

Purpose of the Study:

• To elucidate the role of inflammation in the elevated cardiovascular risk observed in rheumatoid arthritis.
• To explore the impact of inflammation on atherosclerosis development and progression in RA.
• To evaluate the cardiovascular protective effects of specific RA treatments.

Main Methods:

• Review of epidemiologic data on cardiovascular disease risk in rheumatoid arthritis.
• Analysis of the interplay between inflammation, lipid metabolism, and atherosclerosis.
• Examination of the cardiovascular effects of methotrexate and TNF antagonists in RA patients.

Main Results:

• Inflammation significantly contributes to the pathogenesis of atherosclerosis and amplifies cardiovascular risk in RA.
• Atherosclerosis is fundamentally an inflammatory disease, with inflammatory modifications of lipoproteins accelerating atherogenesis.
• Treatments like methotrexate and TNF antagonists demonstrate cardiovascular protective effects in RA, particularly in patients with treatment response.

Conclusions:

• Effective management of cardiovascular risk in RA requires controlling disease activity with disease-modifying anti-rheumatic drugs.
• Addressing traditional cardiovascular risk factors remains essential alongside inflammation control in RA patients.
• Targeting inflammation is a critical strategy for mitigating cardiovascular complications in rheumatoid arthritis.